Semiphysiologically based pharmacokinetic model for midazolam and CYP3A mediated metabolite 1-OH-midazolam in morbidly obese and weight loss surgery patients

CPT: Pharmacometrics and Systems Pharmacology

Volumn 5, Issue 1, 2016, Pages 20-30

  Brill, M J E ^a,b   Valitalo, P A J ^a   Darwich, A S ^c   Van Ramshorst, B ^b   Van Dongen, H P A ^b   Rostami Hodjegan, A ^c   Danhof, M ^a   Knibbe, C A J ^a,b  

^a LEIDEN UNIVERSITY   (Netherlands)

^b ST ANTONIUS HOSPITAL   (Netherlands)

^c UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPRAZOLAM; CYCLOSPORIN; CYTOCHROME P450 3A; MIDAZOLAM; TRIAZOLAM; CYP3A PROTEIN, HUMAN;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; ENZYME ACTIVITY; FEMALE; HEPATIC CLEARANCE; HUMAN; INTESTINE; INTRINSIC CLEARANCE; LIVER; LIVER BLOOD FLOW; MALE; MORBID OBESITY; OBSERVATIONAL STUDY; PLASMA CLEARANCE; PRIORITY JOURNAL; PROSPECTIVE STUDY; SURGICAL TECHNIQUE; WEIGHT LOSS SURGERY; WEIGHT REDUCTION; ALGORITHM; BIOLOGICAL MODEL; CHEMISTRY; ENZYMOLOGY; GASTROINTESTINAL TRACT; INTRAVENOUS DRUG ADMINISTRATION; METABOLISM; OBESITY, MORBID; ORAL DRUG ADMINISTRATION;

ADMINISTRATION, ORAL; ALGORITHMS; CYTOCHROME P-450 CYP3A; GASTROINTESTINAL TRACT; HUMANS; INJECTIONS, INTRAVENOUS; LIVER; MIDAZOLAM; MODELS, BIOLOGICAL; OBESITY, MORBID; OBSERVATIONAL STUDIES AS TOPIC;

EID: 84956838082     PISSN: None     EISSN: 21638306     Source Type: Journal    
DOI: 10.1002/psp4.12048     Document Type: Article

References (42)

1. Buchwald, H. et al. Bariatric surgery: A systematic review and meta-analysis. JAMA 292, 1724-1737 (2004).
2. Buchwald, H. & Oien, D.M. Metabolic/bariatric surgery worldwide 2011. Obes. Surg. 23, 427-436 (2013).
3. Lazzati, A., Guy-Lachuer, R., Delaunay, V., Szwarcensztein, K. & Azoulay, D. Bariatric surgery trends in France: 2005-2011. Surg. Obes. Relat. Dis. 10, 328-334 (2014).
4. Kral, J.G. & Naslund, E. Surgical treatment of obesity. Nat. Clin. Pract. Endocrinol. Metab. 3, 574-583 (2007).
5. Edwards, A. & Ensom, M.H. Pharmacokinetic effects of bariatric surgery. Ann. Pharmacother. 46, 130-136 (2012).
6. Sjostrom, L. et al. Lifestyle, diabetes, and cardiovascular risk factors 10 years after bariatric surgery. N. Engl. J. Med. 351, 2683-2693 (2004).
7. Brocks, D.R., Ben-Eltriki, M., Gabr, R.Q. & Padwal, R.S. The effects of gastric bypass surgery on drug absorption and pharmacokinetics. Expert Opin. Drug Metab. Toxicol. 8, 1505-1519 (2012).
8. Brill, M.J. et al. The pharmacokinetics of the CYP3A substrate midazolam in morbidly obese patients before and one year after bariatric surgery. Pharm. Res. 32, 3927-3936 (2015).
9. Tandra, S., Chalasani, N., Jones, D.R., Mattar, S., Hall, S.D. & Vuppalanchi, R. Pharmacokinetic and pharmacodynamic alterations in the Roux-en-Y gastric bypass recipients. Ann. Surg. 258, 262-269 (2013).
10. Jamei, M. et al. Population-based mechanistic prediction of oral drug absorption. AAPS J. 11, 225-237 (2009).
11. Heizmann, P. & Ziegler, W.H. Excretion and metabolism of 14C-midazolam in humans following oral dosing. Arzneimittelforschung 31, 2220-2223 (1981).
12. Zanger, U.M. & Schwab, M. Cytochrome P450 enzymes in drug metabolism: regulation of gene expression, enzyme activities, and impact of genetic variation. Pharmacol. Ther. 138, 103-141 (2013).
13. Yang, J., Kjellsson, M., Rostami-Hodjegan, A. & Tucker, G.T. The effects of dose staggering on metabolic drug-drug interactions. Eur. J. Pharm. Sci. 20, 223-232 (2003).
14. Frechen, S. et al. A semiphysiological population pharmacokinetic model for dynamic inhibition of liver and gut wall cytochrome P450 3A by voriconazole. Clin. Pharmacokinet. 52, 763-781 (2013).
15. Flockhart, A. Cytochrome P450 drug interaction table. 〈http://www.greenbridgemed. com/wp-content/uploads/2011/09/Drugs-using-P450-Hepatic-metabolism.pdf〉.
16. Brill, M.J. et al. Midazolam pharmacokinetics in morbidly obese patients following semi-simultaneous oral and intravenous administration: A comparison with healthy volunteers. Clin. Pharmacokinet. 53, 931-941 (2014).
17. Beal, S., Sheiner, L.B., Boeckmann, A. & Bauer RJ. NONMEM user's guides (1988-2011) (Ellicott City, MD, 2011).
18. Savic, R.M., Jonker, D.M., Kerbusch, T. & Karlsson, M.O. Implementation of a transit compartment model for describing drug absorption in pharmacokinetic studies. J. Pharmacokinet. Pharmacodyn. 34, 711-726 (2007).
19. Yang, J., Jamei, M., Yeo, K.R., Tucker, G.T. & Rostami-Hodjegan, A. Prediction of intestinal first-pass drug metabolism. Curr. Drug Metab. 8, 676-684 (2007).
20. Yang, J., Jamei, M., Yeo, K.R., Rostami-Hodjegan, A. & Tucker, G.T. Misuse of the well-stirred model of hepatic drug clearance. Drug Metab. Dispos. 35, 501-502 (2007).
21. Thummel, K.E. et al. Oral first-pass elimination of midazolam involves both gastrointestinal and hepatic CYP3A-mediated metabolism. Clin. Pharmacol. Ther. 59, 491-502 (1996).
22. Gorski, J.C., Jones, D.R., Haehner-Daniels, B.D., Hamman, M.A., O'Mara, E.M. Jr. & Hall, S.D. The contribution of intestinal and hepatic CYP3A to the interaction between midazolam and clarithromycin. Clin. Pharmacol. Ther. 64, 133-143 (1998).
23. Lee, J.I., Chaves-Gnecco, D., Amico, J.A., Kroboth, P.D., Wilson, J.W. & Frye, R.F. Application of semisimultaneous midazolam administration for hepatic and intestinal cytochrome P450 3A phenotyping. Clin. Pharmacol. Ther. 72, 718-728 (2002).
24. Brown, R.P., Delp, M.D., Lindstedt, S.L., Rhomberg, L.R. & Beliles, R.P. Physiological parameter values for physiologically based pharmacokinetic models. Toxicol. Ind. Health 13, 407-484 (1997).
25. Young, J.F. et al. Human organ/tissue growth algorithms that include obese individuals and black/white population organ weight similarities from autopsy data. J. Toxicol. Environ. Health A 72, 527-540 (2009).
26. Williams, L.R. & Leggett, R.W. Reference values for resting blood flow to organs of man. Clin. Phys. Physiol. Meas. 10, 187-217 (1989).
27. Keizer, R.J. et al. Incorporation of concentration data below the limit of quantification in population pharmacokinetic analyses. Pharmacol. Res. Perspect. 3, e00131 (2015).
28. Jamei, M., Marciniak, S., Feng, K., Barnett, A., Tucker, G. & Rostami-Hodjegan, A. The Simcyp population-based ADME simulator. Expert Opin. Drug Metab. Toxicol. 5, 211-223 (2009).
29. Ghobadi, C. et al. Application of a systems approach to the bottom-up assessment of pharmacokinetics in obese patients: expected variations in clearance. Clin. Pharmacokinet. 50, 809-822 (2011).
30. Fisher, C.D. et al. Hepatic cytochrome P450 enzyme alterations in humans with progressive stages of nonalcoholic fatty liver disease. Drug Metab. Dispos. 37, 2087-2094 (2009).
31. Kolwankar, D. et al. Association between nonalcoholic hepatic steatosis and hepatic cytochrome P-450 3A activity. Clin. Gastroenterol. Hepatol. 5, 388-393 (2007).
32. Alexander, J.K., Dennis, E.W., Smith, W.G., Amad, K.H., Duncan, W.C. & Austin, R.C. Blood volume, cardiac output, and distribution of systemic blood flow in extreme obesity. Cardiovasc. Res. Cent. Bull. 1, 39-44 (1962-1963).
33. Ijaz, S., Yang, W., Winslet, M.C. & Seifalian, A.M. Impairment of hepatic microcirculation in fatty liver. Microcirculation 10, 447-456 (2003).
34. Lassailly, G. et al. Bariatric surgery reduces features of nonalcoholic steatohepatitis in morbidly obese patients. Gastroenterology 149, 379-388; quiz e15-e16 (2015).
35. Greenblatt, D.J., Abernethy, D.R., Locniskar, A., Harmatz, J.S., Limjuco, R.A. & Shader, R.I. Effect of age, gender, and obesity on midazolam kinetics. Anesthesiology 61, 27-35 (1984).
36. Olivares-Morales, A., Kamiyama, Y., Darwich, A.S., Aarons, L. & Rostami-Hodjegan, A. Analysis of the impact of controlled release formulations on oral drug absorption, gut wall metabolism and relative bioavailability of CYP3A substrates using a physiologically-based pharmacokinetic model. Eur. J. Pharm. Sci. 67, 32-44 (2015).
37. Venkataramanan, R., Ptachcinski, R.J., Burckart, G.J., Yang, S. & Starzl, T.E. Extraction ratio of cyclosporine in a liver transplant patient with organ rejection. J. Pharm. Sci. 74, 901-902 (1985).
38. Ohtsuka, T. et al. Alprazolam as an in vivo probe for studying induction of CYP3A in cynomolgus monkeys. Drug Metab. Dispos. 38, 1806-1813 (2010).
39. Kroboth, P.D., McAuley, J.W., Kroboth, F.J., Bertz, R.J. & Smith, R.B. Triazolam pharmacokinetics after intravenous, oral, and sublingual administration. J. Clin. Psychopharmacol. 15, 259-262 (1995).
40. Masica, A.L., Mayo, G. & Wilkinson, G.R. In vivo comparisons of constitutive cytochrome P450 3A activity assessed by alprazolam, triazolam, and midazolam. Clin. Pharmacol. Ther. 76, 341-349 (2004).
41. Ito, K., Ogihara, K., Kanamitsu, S. & Itoh, T. Prediction of the in vivo interaction between midazolam and macrolides based on in vitro studies using human liver microsomes. Drug Metab. Dispos. 31, 945-954 (2003).
42. Mandema, J.W., Tuk, B., van Steveninck, A.L., Breimer, D.D., Cohen, A.F. & Danhof, M. Pharmacokinetic-pharmacodynamic modeling of the central nervous system effects of midazolam and its main metabolite alpha-hydroxymidazolam in healthy volunteers. Clin. Pharmacol. Ther. 51, 715-728 (1992).